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Avian inﬂuenza (AI) A subtype H9N2 virus belongs toOrthomyxoviridae family
and causes low-pathogenic disease AI. The use of gamma-irradiated viral antigens has
been developed in the production of effective vaccines. In this research, LPAIV H9N2
strain, A/Chicken/IRN/Ghazvin/2001, was multiplied on SPF eggs and irradiated by a
Nordian gamma cell instrument. Irradiated and non-irradiated AI virus (AIV) samples
were titrated by EID50 method and hemagglutinin (HA) antigen was analyzed by HA
test as the WHO pattern method. Infectivity of irradiated virus was determined by egg
inoculation method during four blind cultures. The results showed that after increasing
the dose of gamma radiation, virus titer gradually decreased. D10 value and optimum
dose for complete virus inactivation were calculated by dose/response curve, 3.36 and
29.52 kGy, respectively. In addition, HA antigenicity of gamma-irradiated virus
samples from 0 to 30 kGy was not changed. The results of safety test for gamma-
irradiated AIV samples showed complete inactivation with gamma ray doses 30 and
35 kGy, without any multiplication on eggs after four blind cultures. According to the
results of HA antigen assay and safety test, the gamma-irradiated and complete
inactivated AIV subtype H9N2 is a good candidate as an inactivated immunogenic
agent for poultry vaccination.
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Introduction
Avian inﬂuenza (AI) is caused by speciﬁed viruses that are members of the
family Orthomyxoviridae and placed in the genus Inﬂuenza virus A. There are
three inﬂuenza genera – A, B, and C; only Inﬂuenza A viruses are known to infect
birds [1].
Inﬂuenza viruses type A are classiﬁed into different subtypes, based on two
surface glycoproteins [hemagglutinin (HA) and neuraminidase] [2]. AI A subtype
H9N2 virus is circulating in domestic poultry worldwide. Although this subtype is
generally not highly pathogenic for avian species, this virus has recently been
transmitted to mammalian species, including humans [3]. Inﬂuenza viruses type A
are divided into two groups according to the virulence for chickens. Highly
pathogenic AI (HPAI) viruses cause rapid mortality up to 100%, whereas non-HPAI
viruses including mildly pathogenic, low-pathogenic AI virus (AIV) (LPAIV),
and non-pathogenic AIV may cause mild respiratory disease with low mortality or
may not cause disease [4]. The HPAI viruses have been obtained from H5 or
H7 subtypes [5]. Inﬂuenza A viruses of subtypes H9N2 and H5N1 are low pathogenic
and highly pathogenic AIV, respectively, and considered as zoonotic subtypes.
The use of gamma-irradiated viral antigens has been developed in the
production of effective vaccines as well as for diagnostic purposes. The dose of
gamma radiation for viral inactivation is related to the virus concentration, the size
of the particles containing viral genomes, and the temperature of irradiation. The
aim of this study is using gamma irradiation to inactivate AI virus A subtype H9N2
without any change in HA antigen characteristics as an immunogenic to induce
immune responses.
Materials and Methods
Virus multiplication
The isolated virus that is used in this study was LPAIV H9N2 strain,
A/Chicken/IRN/Ghazvin/2001. The viral suspension (0.2 ml) was inoculated into
the allantoic sac of embryonated SPF chicken eggs of 9–11 days incubation. The
eggs are incubated at 37 °C (range: 35–39 °C) for 2–5 days. All the eggs remaining
at the end of the incubation period were chilled to 4 °C for 4 h or overnight, and the
allantoic ﬂuids were harvested 96 h after inoculation and centrifuged at 1,500× g
at 4 °C for 10 min to separate RBC and other cells. The allantoic ﬂuids were tested
using hemagglutination test, each negative sample was tested again and each
positive sample was stored in −70 °C [1].
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The infectious viral titer was determined using 10-day-old embryonated SPF
eggs and egg infectious dose 50 (EID50) was calculated according to Reed and
Muench [6] and OIE manual.
Gamma irradiation and inactivation of virus samples
Gamma radiation was used for the inactivation of AI A subtype H9N2
viruses. AIV was irradiated by a Nordian model 220 gamma cell instrument at a
dose rate of 2.07 Gy/s and activity of 8677 Ci to cripple inﬂuenza virus genomic
RNA and to inactivate virus infectivity. Gamma ray doses of 5, 10, 15, 20, 25, and
30 kGy were administered for the frozen virus samples and three sample replicates
were irradiated for each dose. The titers of irradiated AIV samples were ﬁrst
obtained by EID50 method, and then a dose/response curve was drawn using
Origin software. The D10 value (dose of gamma radiation, which can decrease one
logarithmic cycle of virus population) and optimum dose of gamma rays for AIV
inactivation were determined according to the dose/response curve. Finally, 50 ml
of the AIV was irradiated by the optimized dose of gamma ray and used for safety
test to conﬁrm complete virus inactivation.
Virus titration of irradiated and non-irradiated samples
Virus titers were determined in embryonated SPF chicken EID50/ml by
endpoint dilution and the calculation method of Reed andMuench [6]. The EID50 is
a biological method to determine the amount of infectious virus in a sample by
determining the highest dilution of the sample that can infect 50% of the embryo-
nated chicken eggs. This assay entailed performing the serial dilutions of the viral
sample and 0.1 ml of each dilution was inoculated for each egg. To determine the
best dilution to produce a 50% positive result, the Reed–Muench [6] method is used.
This method requires the use of three or more eggs per dilution to determine the 50%
endpoint by performing a hemagglutination assay for each inoculated egg.
HA antigen assay
HA antigen of irradiated and non-irradiated viral samples was analyzed
using hemagglutination test as the WHO pattern method. An amount of 50 μl of
phosphate-buffered saline (PBS) was added to wells 2–12, and 100 μl of each
tested virus to the ﬁrst well. Twofold serial dilutions were made by transferring
50 μl from the ﬁrst well to successive well-11 and discarded the ﬁnal 50 μl from
well-11. Well-12 contained only PBS as RBC control. An amount of 50 μl of
GAMMA IRRADIATION TO INACTIVATE AVIAN INFLUENZA VIRUS SUBTYPE H9N2 165
Acta Microbiologica et Immunologica Hungarica 65, 2018
0.5% RBC suspension was added to each well on the plate. Then, the plates were
mixed and incubated at room temperature for 30 min. The titers of viruses were
recorded after 30 min by tipping plates and reading RBC buttons that stream. The
highest dilution of virus that causes complete hemagglutination is considered to be
the HA titration end point. The HA titer is the reciprocal of the dilution of virus in
the last well with complete hemagglutination [7].
Safety test
Infectivity of irradiated virus samples (by different doses of gamma ray: 25,
30, and 35 kGy) was determined by eggs inoculation method during four blind
cultures on eggs. All of the irradiated virus samples were inoculated on embryonated
SPF chicken eggs of 9–11 days; also their titration was obtained by EID50 methods.
Results
The results of virus titration by EID50 method for non-irradiated AIV
sample were calculated and shown in Table I. It was 108.77 ml−1 and the virus
titration for irradiated virus samples was calculated (Table II). According to the
increasing dose of gamma radiation, virus titration decreased gradually.
Proportionate distance ðPdÞ= fð%positive above 50%Þ − 50%g=
fð%positive above 50%Þ − ð%positive below 50%Þg,
Pd= ð77 − 50Þ=ð77 − 42Þ= 0.77:
ðLog dilution above 50%Þ þ ðPd × log dilution factorÞ= log ID 50,
−7þ ½0.77 × ð− 1Þ= − 7.77:
EID50= 107.77=0.1ml,
EID50= 108.77=ml:
Table I. Titration of non-irradiated avian inﬂuenza A subtype H9N2 virus by Reed and Muench method
(EID50/ml)
Dilution Positive Negative
Cumulative no.
positive (A)
Cumulative no.
negative (B) A/(A+B)
Percentage
(%)
10−6 4 1 11 1 11/12 91
10−7 4 1 7 2 7/9 77
10−8 3 2 3 4 3/7 42
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D10 value and optimum dose for complete virus inactivation were calculated
by dose/response curve (Figure 1), 3.36 and 29.52 kGy, respectively.
HA antigen assay was carried out and the results showed that the HA antigeni-
city of gamma-irradiated virus samples from 0 to 30 kGywas not changed (Table III).
The results of safety test for gamma-irradiated AIV subtype H9N2 samples
showed complete inactivation with gamma ray doses 30 and 35 kGy, without any
multiplication on eggs after four blind cultures (Table IV). According to the results
of HA antigen assay and safety test, the gamma-irradiated and complete inacti-
vated AIV subtype H9N2 is a good candidate as an inactivated immunogenic
agent for poultry vaccination.
Discussion
Nowadays, a wide range of novel methods have been described to
inactivate viruses, such as ethylenimine derivatives [8], hydrogen peroxide [9],
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Figure 1. Dose–response curve for irradiated avian inﬂuenza A subtype H9N2 virus
Table II. Titration of gamma-irradiated avian inﬂuenza A subtype H9N2 virus samples
Dose of gamma radiation (kGy) 0 5 10 15 20
Virus titration (EID50/ml) 108.77 105.47 104.83 104.17 102.33
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gamma irradiation [10, 11] and UV treatment [12], heat [13], etc. [14].
Nonetheless, only formaldehyde and β-propiolactone are widely used for
inactivation of viral vaccines for decades. Formaldehyde is the most widely
used inactivating agent for vaccine purposes and many pathogens have been
subjected to the irreversible modiﬁcations by cross-linking of various amino
acids. In addition, the effects of formaldehyde are a great diversity of modiﬁca-
tions (methyl groups, Schiff bases, and methylene bridges) and other mechan-
isms are subject of investigation in several recent studies [15–18]. But safety of
formaldehyde is very complicated. It is not acutely toxic as ingestion of many
milliliters is tolerated. WHO International Agency for Research on Cancer
(IARC) in 1995 also classiﬁed formaldehyde as a probable human carcinogen.
Further information and evaluation of all known data led the IARC to reclassify
formaldehyde as a known human carcinogen, associated with nasal sinus cancer
and nasopharyngeal cancer [19, 20]. Recent studies have also shown a positive
correlation between exposure to formaldehyde and the development of leukemia,
particularly myeloid leukemia [20]. In addition, formaldehyde can cause
allergies [20].
Table III. The results of hemagglutinin antigen assay for irradiated and non-irradiated avian inﬂuenza A
subtype H9N2 virus samples
Dose of
gamma
radiation
(kGy)
Virus dilution
1/2 1/4 1/8 1/16 1/32 1/64 1/128 1/256 1/512 1/1024
Negative
control
0 + + + + + + + + − − −
2 + + + + + + + + − − −
5 + + + + + + + + + − −
10 + + + + + + + + − − −
15 + + + + + + + + − − −
20 + + + + + + + + − − −
30 + + + + + + + + − − −
Table IV. The results of safety test for gamma-irradiated avian inﬂuenza A subtype H9N2 virus
Dose of gamma
radiation (kGy)
Passage number
First passage Second passage Third passage Fourth passage
20 Positive Positive Positive Positive
30 Negative Negative Negative Negative
35 Negative Negative Negative Negative
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In July 1998, H9N2 subtype inﬂuenza A virus (LPAIV) was reported in the
industrial poultry population of Iran [21]. Due to the widespread occurrence of the
H9N2 LPAIV, and the zoonotic potential of the virus, vaccination of chicken with
water-in-oil emulsion-inactivated vaccine was employed to control the disease in
the country [22].
The conventional H9N2 subtype inﬂuenza A vaccine was inactivated by
formaldehyde, it makes some residue in the vaccine. In this study, gamma
irradiation was used to inactivate virus, without any residue and without any
change in HA antigen characteristics. Therefore, the irradiated inactivated H9N2
subtype inﬂuenza A virus can be used as an immunogenic to induce immune
responses.
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